| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c999da6ceacdb7989620516d686b29da |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0019
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7068
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-706
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/B65B3-003
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/B65B7-161 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7068
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/B65B3-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/B65B7-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-706 |
| filingDate |
2013-10-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2017-06-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d1966a0bae5bf816b4193432d51ccdb3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b5d30e6a4638f3106cd07c386936f4c9
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_14656ca837f7c25f9ea36aabe0c6be45
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_77c29b40907e67314e4b92b406dd819a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f702b68a137da150f4f6ef05f8b3d253 |
| publicationDate |
2017-06-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-9669048-B2 |
| titleOfInvention |
Stable pharmaceutical composition of 5-aza-2′-deoxycitidine |
| abstract |
Described herein are ready to use, non-aqueous pharmaceutical compositions comprising 5-aza-2′-deoxycitidine and at least one aprotic solvent. The pharmaceutical compositions may further comprise at least one protic solvent. Also described are processes for preparing the pharmaceutical compositions and their use for the treatment of patients suffering from myelodysplastic syndromes. |
| priorityDate |
2012-10-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |